update aRtICLe Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid

Vimal Mehta, Raman Puri, P. Barton Duell, S. S. Iyengar, Nathan D. Wong, Jamal Yusuf, Saibal Mukhopadhyay, Akshaya Pradhan, Arumugam Muruganathan, S. K. Wangnoo, Dheeraj Kapoor, Ashu Rastogi, Mangesh H. Tiwaskar, Kunal Mahajan, S. N. Narasingan, Rajeev Agarwala, Neil Bordoloi, Kumar Soumitra, Rabin Chakraborty, Sadanand ShettyBansi Saboo, Aziz Khan, D. Prabhakar, Narendra Nath Khanna, Ashwani Mehta, Manish Bansal, Ravi Kasliwal, Rahul Mehrotra, Milan Chag, Altamesh Sheikh, Gururaj Balvantrao Sattur, P. C. Manoria, K. K. Pareek, A. K. Pancholia, Rashida Patanwala Melinkeri, Rashmi Nanda, Dinesh Kalra

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Lipid-lowering therapy plays a crucial role in reducing adverse cardiovascular (CV) events in patients with established atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia. Lifestyle interventions along with high-intensity statin therapy are the first-line management strategy followed by ezetimibe. Only about 20-30% of patients who are on maximally tolerated statins reach recommended low-density lipoprotein cholesterol (LDL-C) goals. Several factors contribute to the problem, including adherence issues, prescription of less than high-intensity statin therapy, and de-escalation of statin dosages, but in patients with very high baseline LDL-C levels, including those with familial hypercholesterolemia and those who are intolerant to statins, it is critical to expand our arsenal of LDL-C-lowering medications. Moreover, in the extreme risk group of patients with an LDL-C goal of ≤30 mg/dL according to the Lipid Association of India (LAI) risk stratification algorithm, there is a significant residual risk requiring the addition of non-statin drugs to achieve LAI recommended targets. This makes bempedoic acid a welcome addition to the existing non-statin therapies such as ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. A low frequency of muscle-related side effects, minimal drug interactions, a significant reduction in high-sensitivity C-reactive protein (hsCRP), and a lower incidence of new-onset or worsening diabetes make it a useful adjunct for LDL-C lowering. However, the CV outcomes trial results are still pending. In this LAI consensus document, we discuss the pharmacology, indications, contraindications, advantages, and evidence-based recommendations for the use of bempedoic acid in clinical practice.

Original languageEnglish (US)
Pages (from-to)67-75
Number of pages9
JournalJournal of Association of Physicians of India
Issue number9
StatePublished - Sep 2022

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'update aRtICLe Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid'. Together they form a unique fingerprint.

Cite this